Skip Navigation


JAC Advance Access originally published online on December 4, 2003
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
53/1/4    most recent
dkh029v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (29)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Zeldin, R. K.
Right arrow Articles by Petruschke, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zeldin, R. K.
Right arrow Articles by Petruschke, R. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


Journal of Antimicrobial Chemotherapy (2004) 53, 4-9
© 2004 The British Society for Antimicrobial Chemotherapy

Leading Article

Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients

Robert K. Zeldin* and Richard A. Petruschke

Clinical Development, Merck & Co., Inc., West Point, PA, USA

Boosted protease inhibitor regimens combine ritonavir with a second, ‘boosted’ protease inhibitor to enhance patient exposure to the latter agent, thereby preventing or overcoming resistance and allowing less frequent dosing, potentially improving adherence. The advantages offered by ritonavir boosting are primarily attributable to the drug’s pharmacokinetic properties. Ritonavir’s inhibition of the cytochrome P-450 CYP3A4 enzyme reduces the metabolism of concomitantly administered protease inhibitors and changes their pharmacokinetic parameters, including area under the curve (AUC), maximum concentration (Cmax), minimum concentration (Cmin) and half-life (t1/2). As a result, the bioavailability of the boosted protease inhibitor is increased and improved penetration into HIV reservoirs may be achieved. Boosted protease inhibitor regimens that utilize a low dose of ritonavir (100–200 mg) appear to offer the best balance of efficacy and tolerability. At this dose, ritonavir boosts the bioavailability of the second protease inhibitor without contributing significantly to the side effect profile of the regimen. In clinical trials, regimens boosted with low dose ritonavir have demonstrated high levels of viral suppression in both antiretroviral naïve patients and patients who previously failed antiretroviral therapy, including protease inhibitor therapy. Side effects observed have generally been similar to those associated with the boosted protease inhibitor. Based upon their enhanced drug exposure and demonstrated efficacy, the boosted ritonavir regimens should be among the first options considered for use in clinical practice.

Keywords: pharmacokinetics, pharmacodynamics, clinical experience, dosing, tolerability

* Corresponding author. Tel: +1-215-328-2280; Fax: +1-215-328-2444; E-mail: robert_zeldin{at}merck.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
J. van der Lugt, R. S. Autar, S. Ubolyam, E. F. Garcia, J. Sankote, A. Avihingson, T. Chuenyam, D. A. Cooper, J. Lange, P. Phanuphak, et al.
Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults
J. Antimicrob. Chemother., May 1, 2008; 61(5): 1145 - 1153.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
C. Healan-Greenberg, J. F. Waring, D. J. Kempf, E. A. G. Blomme, R. G. Tirona, and R. B. Kim
A Human Immunodeficiency Virus Protease Inhibitor Is a Novel Functional Inhibitor of Human Pregnane X Receptor
Drug Metab. Dispos., March 1, 2008; 36(3): 500 - 507.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
A. F. Y. Poon, S. L. Kosakovsky Pond, D. D. Richman, and S. D. W. Frost
Mapping Protease Inhibitor Resistance to Human Immunodeficiency Virus Type 1 Sequence Polymorphisms within Patients
J. Virol., December 15, 2007; 81(24): 13598 - 13607.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. Youle
Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients
J. Antimicrob. Chemother., December 1, 2007; 60(6): 1195 - 1205.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
V. Dixit, N. Hariparsad, F. Li, P. Desai, K. E. Thummel, and J. D. Unadkat
Cytochrome P450 Enzymes and Transporters Induced by Anti-Human Immunodeficiency Virus Protease Inhibitors in Human Hepatocytes: Implications for Predicting Clinical Drug Interactions
Drug Metab. Dispos., October 1, 2007; 35(10): 1853 - 1859.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
M. Boffito, D. Maitland, and A. Pozniak
Practical Perspectives on the Use of Tipranavir in Combination With Other Medications: Lessons Learned From Pharmacokinetic Studies
J. Clin. Pharmacol., February 1, 2006; 46(2): 130 - 139.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. M. Hammer
Clinical practice. Management of newly diagnosed HIV infection.
N. Engl. J. Med., October 20, 2005; 353(16): 1702 - 1710.
[Full Text] [PDF]

Home page
 Hum Mol GenetHome page
W. Sadee and Z. Dai
Pharmacogenetics/genomics and personalized medicine
Hum. Mol. Genet., October 15, 2005; 14(suppl_2): R207 - R214.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
S. A. Krikorian and D. C. Rudorf
Drug-Drug Interactions and HIV Therapy: What Should Pharmacists Know?
Journal of Pharmacy Practice, August 1, 2005; 18(4): 278 - 294.
[Abstract] [PDF]

Home page
 Am J Health Syst PharmHome page
J. D. Scott
Simplifying the treatment of HIV infection with ritonavir-boosted protease inhibitors in antiretroviral-experienced patients
Am. J. Health Syst. Pharm., April 15, 2005; 62(8): 809 - 815.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
F. S. Rhame, S. L. Rawlins, R. A. Petruschke, T. A. Erb, G. A. Winchell, H. M. Wilson, J. M. Edelman, and M. A. Abramson
Pharmacokinetics of Indinavir and Ritonavir Administered at 667 and 100 Milligrams, Respectively, Every 12 Hours Compared with Indinavir Administered at 800 Milligrams Every 8 Hours in Human Immunodeficiency Virus-Infected Patients
Antimicrob. Agents Chemother., November 1, 2004; 48(11): 4200 - 4208.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
C. Armbruster, G. M. Stiegler, B. A. Vcelar, W. Jager, U. Koller, R. Jilch, C. G. Ammann, M. Pruenster, H. Stoiber, and H. W. D. Katinger
Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12
J. Antimicrob. Chemother., November 1, 2004; 54(5): 915 - 920.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.